October 15, 2024

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH
Go back

Daiichi Sankyo’s European roots date back to the 1980s with branches in Düsseldorf. In 1990, Sankyo acquired Luitpold-Werke, a German pharmaceutical company, expanding operations to Pfaffenhofen, Germany, and Altkirch, France. In 2006, Daiichi and Sankyo merged, with European headquarters in Munich. Now present in 13 countries, Daiichi Sankyo employs over 2,000 people, making it one of Europe’s largest Japanese pharmaceutical companies. It develops and markets treatments for hypertension, dyslipidemia, infections, cardiovascular diseases, and thrombotic disorders.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
BioMed X and Servier Launch First XSeed Labs in Europe

BioMed X and Servier Launch First XSeed Labs in Europe

Heidelberg, Germany / Paris, France, July 9th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new initiative with Servier. The two partners will implement BioMed X’s proven XSeed Labs incubator model at Servier’s research and development site in Paris-Saclay. This new XSeed Labs – the first of its kind in Europe […]

read more
Investigating kinase activity in living cells

Investigating kinase activity in living cells

Scientists build molecular recording tool The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular processes. Scientists at the Max Planck Institute for Medical Research in Heidelberg have now developed a novel molecular tool that can monitor these kinase activities both spatially and temporally. This […]

read more
The evolution of cancer cells decoded

The evolution of cancer cells decoded

Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center (DKFZ) have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp